GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Defence Therapeutics Inc (XCNQ:DTC) » Definitions » Common Stock

Defence Therapeutics (XCNQ:DTC) Common Stock : C$17.90 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Defence Therapeutics Common Stock?

Defence Therapeutics's quarterly common stock increased from Mar. 2023 (C$14.99 Mil) to Sep. 2023 (C$17.15 Mil) and increased from Sep. 2023 (C$17.15 Mil) to Dec. 2023 (C$17.90 Mil).

Defence Therapeutics's annual common stock increased from Jun. 2020 (C$2.40 Mil) to Jun. 2021 (C$7.97 Mil) and increased from Jun. 2021 (C$7.97 Mil) to Jun. 2022 (C$9.33 Mil).


Defence Therapeutics Common Stock Historical Data

The historical data trend for Defence Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Defence Therapeutics Common Stock Chart

Defence Therapeutics Annual Data
Trend Jun20 Jun21 Jun22
Common Stock
2.40 7.97 9.33

Defence Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.52 10.70 14.99 17.15 17.90

Defence Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Defence Therapeutics (XCNQ:DTC) Business Description

Traded in Other Exchanges
Address
200 Burrard Street, Suite 1680, Vancouver, BC, CAN, V6C3L6
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development.
Executives
Sarkis Meterissian Director